IMPLEMENTATION OF A PROCESS OPTIMIZATION PROTOCOL FOR THE PREPARATION OF READY-TO-USE (RTU) INTRACAMERAL CEFUROXIME FOR ENDOPHTHALMITIS PROPHYLAXIS (EP) AFTER CATARACT SURGERY

C. FERNANDEZ LOPEZ1, C. MEDARDE CABALLERO1, R. LOPEZ SEPULVEDA2, C. VALENCIA SOTO2, S. RUIZ FUENTES1, S. BELDA RUSTARAZO1, C. GOMEZ PEÑA1, C. GARCIA FERNANDEZ1, A. CABALLERO ROMERO1, D. BLANQUEZ MARTINEZ1

1Hospital Universitario San Cecilio, Pharmacy, Granada, Spain. 2Hospital Virgen de las Nieves, Pharmacy, Granada, Spain.

Background

The use of intracameral cefuroxime is becoming more widely accepted for endophthalmitis prophylaxis (EP) after cataract surgery. Recently, the European Medicines Agency approved a single, sterile, unit-dose of intracameral cefuroxime in a few countries of Europe.

Purpose

To evaluate the economic saving result of the implementation of an optimization protocol for the elaboration of ready-to-use (RTU) intracameral cefuroxime syringes from the cefuroxime 1500mg vial.

Materials and Methods

A review of the literature was made for the development of the optimization protocol. To evaluate the economic savings, the cost generated by the consumption of cefuroxime 1500mg vials in the elaboration of RTU syringes since the implementation of the protocol was compared to the costs if the commercialized unit-dose of intracameral cefuroxime would have been used.

Results

Between January and July 2013 five vials of Cefuroxime 1500mg were used to elaborate 1000 RTU cefuroxime syringes, with a cost of 14.56 € (PVP: 145.6€/50 vials). If the commercialized unit dose would have been used, for the same administrations the cost would have been 12164 € (PVP: 121.64 €/10vials); meaning a 99.8% reduction on costs.

Conclusions

The implementation of the optimization protocol for the elaboration of RTU intracameral cefuroxime syringes has led to a significant economic saving without compromising the patient’s health.